Characterization of Myostatin and GDF-11
Characterization of Myostatin and GDF-11
批准号:
9247067
负责人:
SE-JIN LEE
金额:
$1.07万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-08 至 2017-08-16
关键词:
AdultAgeAgingAnteriorBinding ProteinsBiochemicalBiological ProcessBiotechnologyClinical TrialsCodeDevelopmentDifferentiation and GrowthDiseaseElderlyEmbryonic DevelopmentFamily memberFiberFunctional disorderGDF11 geneGDF8 geneGene TargetingGenesGeneticGoalsGrowthHeartHomeostasisHypertrophyIn VitroKnock-inLaboratoriesLigandsMusMuscleMuscle FibersMuscular AtrophyMyocardiumNervous system structurePancreasPaperPatientsPatternPharmacologic SubstancePhasePhase III Clinical TrialsPlayProteinsRegulationReportingResearchRoleSignal TransductionSignaling MoleculeSkeletal MuscleSkeletonTestingTherapeuticTherapeutic InterventionTissuesTransforming Growth FactorsWorkage relatedagedbiochemical toolsclinical applicationcombatexperimental studygrowth-differentiation factor 8in vivoin vivo regenerationinhibitor/antagonistinsightinterestmature animalmembermuscle formmuscle regenerationmuscle strengthmuscular systemnephrogenesisnervous system developmentpostnatalpublic health relevancereceptor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The main focus of our research has been to understand the biological functions of two highly related signaling molecules, myostatin (MSTN, GDF-8) and GDF-11, which we discovered in a screen for new transforming growth factor-ß family members. We showed that mice lacking MSTN have dramatic increases in skeletal muscle mass throughout the body, and we and others showed that systemic administration of MSTN inhibitors to mice can promote muscle growth, showing that MSTN acts to limit muscle growth postnatally. Hence, there is extensive interest in targeting MSTN to enhance muscle strength and regeneration, and at least 7 biotechnology and pharmaceutical companies are in phase II/III clinical trials testing myostatin inhibitors in a wide range of disease settings. We showed that GDF-11 plays an important role in axial patterning and in kidney development, and other groups subsequently showed that GDF-11 also regulates the development of the nervous system and pancreas. Gdf11 is expressed widely in adult tissues, and recent studies have suggested that GDF-11 may play an important role in aging. Specifically, circulating GDF-11 levels were reported to decrease with age, and administration of GDF-11 protein to aged mice was reported to reverse age-related tissue dysfunction in the heart, skeletal muscle, and nervous system. Some of these findings have since been challenged by a paper reporting that GDF-11 levels increase with aging and that GDF-11 has a detrimental effect on skeletal muscle regeneration. These findings have raised new questions regarding the roles of MSTN and GDF-11 in adult animals as well as the potential strategies for manipulating the activities of these molecules for clinical applications. A major question in this regard is whether the distinct functions of MSTN and GDF-11 reflect the inherent biochemical differences between these highly related molecules or whether their distinct functions simply reflect their differing pattern of expression. The overall goal of this project is to understand the basis for the distinct functios of these molecules. This project is a continuation of our long-standing effort to understand the mechanisms underlying the regulation and signaling of MSTN and GDF-11 and will utilize the many genetic and biochemical tools that we have developed over many years to target the various components of this regulatory network. The Specific Aims are: to compare the activities of MSTN and GDF-11 in vitro with respect to the roles of known signaling components, including inhibitory binding proteins and receptors; to examine the roles of these binding proteins and receptors in regulating skeletal and cardiac muscle growth and function and skeletal muscle regeneration in vivo; and to carry out gene knock-in experiments in mice in which the MSTN coding sequence is replaced with GDF-11 (and vice versa). The results of these experiments should provide key insights into the mechanistic basis underlying the distinct biological functions
that MSTN and GDF-11 carry out in vivo. We believe that these studies will be crucial for developing strategies to exploit the activities of these molecules for therapeutic intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TGF-beta family members and their binding proteins in aging skeletal muscle
-
批准号:9420283
-
项目类别:
-
资助金额:$50.05万
-
财政年份:2017
-
负责人:SE-JIN LEE
-
依托单位:
TGF-beta family members and their binding proteins in aging skeletal muscle
-
批准号:9264681
-
项目类别:
-
资助金额:$15.61万
-
财政年份:2016
-
负责人:SE-JIN LEE
-
依托单位:
Mechanisms underlying myostatin regulation and activity
-
批准号:8112520
-
项目类别:
-
资助金额:$34.29万
-
财政年份:2010
-
负责人:SE-JIN LEE
-
依托单位:
Mechanisms Underlying Myostatin Regulation and Activity
-
批准号:8690763
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2010
-
负责人:SE-JIN LEE
-
依托单位:
Mechanisms Underlying Myostatin Regulation and Activity
-
批准号:8493785
-
项目类别:
-
资助金额:$32.57万
-
财政年份:2010
-
负责人:SE-JIN LEE
-
依托单位:
Mechanisms Underlying Myostatin Regulation and Activity
-
批准号:8289454
-
项目类别:
-
资助金额:$34.29万
-
财政年份:2010
-
负责人:SE-JIN LEE
-
依托单位:
Mechanisms underlying myostatin regulation and activity
-
批准号:7944957
-
项目类别:
-
资助金额:$36.19万
-
财政年份:2010
-
负责人:SE-JIN LEE
-
依托单位:
Inhibitors of BMP-1/TLD proteases as novel therapeutics for muscular dystrophy
-
批准号:7845516
-
项目类别:
-
资助金额:$16.87万
-
财政年份:2009
-
负责人:SE-JIN LEE
-
依托单位:
LOG-LINEAR MODEL-BASED MULTIFACTOR DIMENSIONALITY
-
批准号:7723462
-
项目类别:
-
资助金额:$0.91万
-
财政年份:2008
-
负责人:SE-JIN LEE
-
依托单位:
Targeting Myostatin Activation for Treatment of Muscular Dystraphy
-
批准号:7648210
-
项目类别:
-
资助金额:$48.71万
-
财政年份:2008
-
负责人:SE-JIN LEE
-
依托单位:
Targeting Myostatin Activation for Treatment of Muscular Dystraphy
-
批准号:7504326
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2007
-
负责人:SE-JIN LEE
-
依托单位:
ROLE OF MYOSTATIN IN CACHEXIA
-
批准号:6847431
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2001
-
负责人:SE-JIN LEE
-
依托单位:
ROLE OF MYOSTATIN IN CACHEXIA
-
批准号:6225287
-
项目类别:
-
资助金额:$31.93万
-
财政年份:2001
-
负责人:SE-JIN LEE
-
依托单位:
ROLE OF MYOSTATIN IN CACHEXIA
-
批准号:6693766
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2001
-
负责人:SE-JIN LEE
-
依托单位:
ROLE OF MYOSTATIN IN CACHEXIA
-
批准号:6626772
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2001
-
负责人:SE-JIN LEE
-
依托单位:
ROLE OF MYOSTATIN IN CACHEXIA
-
批准号:6489396
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2001
-
负责人:SE-JIN LEE
-
依托单位:
GDF-8 (MYOSTATIN) AND GDF-11
-
批准号:2838847
-
项目类别:
-
资助金额:$27.35万
-
财政年份:1997
-
负责人:SE-JIN LEE
-
依托单位:
Characterization of myostatin and GDF-11
-
批准号:6574808
-
项目类别:
-
资助金额:$36.79万
-
财政年份:1997
-
负责人:SE-JIN LEE
-
依托单位:
GDF-8 (MYOSTATIN) AND GDF-11
-
批准号:2866971
-
项目类别:
-
资助金额:$0.78万
-
财政年份:1997
-
负责人:SE-JIN LEE
-
依托单位:
Characterization of Myostatin and GDF-11
-
批准号:8513775
-
项目类别:
-
资助金额:$33.55万
-
财政年份:1997
-
负责人:SE-JIN LEE
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: